Barbara Santevecchi

Barbara Santevecchi, Pharm.D., BCPS, BCIDP

Clinical Assistant Professor

Department: Pharmacotherapy & Translational Research
Business Phone: (352) 594-5892
Business Email: bsantevecchi@cop.ufl.edu

About Barbara Santevecchi

Barbara Santevecchi joined the College of Pharmacy as a Clinical Assistant Professor in the Department of Pharmacotherapy and Translational Research in August 2019. She serves as an Infectious Diseases Clinical Specialist and member of the Antimicrobial Management Program at UF Health Shands Hospital. She received her Doctor of Pharmacy degree from Wingate University School of Pharmacy in Wingate, North Carolina in 2015. Following graduation, she completed PGY1 Pharmacy Practice and PGY2 Infectious Diseases pharmacy residencies at the Medical University of South Carolina in Charleston, South Carolina. After completing residency training, she worked as an Infectious Diseases Clinical Pharmacist at Atrium Health in Charlotte, North Carolina. Barbara holds dual board certification in pharmacotherapy and infectious diseases. Her research interests include HIV/AIDS, microbiology, rapid diagnostics, novel agents for multidrug resistant infections, and antimicrobial stewardship. Barbara has published research in several peer-reviewed journals and has delivered presentations on her research at national meetings.

Accomplishments

Member
2016-Current · Infectious Diseases Society of America
Member
2013-Current · American College of Clinical Pharmacy

Board Certifications

  • Board Certified Infectious Diseases Pharmacist
    Board of Pharmacy Specialties
  • Board Certified Pharmacotherapy Specialist
    Board of Pharmacy Specialties

Research Profile

Research Interests: HIV/AIDS, microbiology, rapid diagnostics, novel agents for multidrug resistant infections, antimicrobial stewardship

Publications

2021
Impact of supplemental individual verbal defense on confidence, engagement, and performance in a team-based learning therapeutics course.
Currents in pharmacy teaching & learning. 13(2):152-158 [DOI] 10.1016/j.cptl.2020.09.010. [PMID] 33454072.
2021
Implementation of a comprehensive intervention focused on hospitalized patients with HIV by an existing stewardship program: successes and lessons learned.
Therapeutic advances in infectious disease. 8 [DOI] 10.1177/20499361211010590. [PMID] 33953916.
2020
Doing More With Less: Review of Dolutegravir-Lamivudine, a Novel Single-Tablet Regimen for Antiretroviral-Naïve Adults With HIV-1 Infection.
The Annals of pharmacotherapy. 54(12):1252-1259 [DOI] 10.1177/1060028020933772. [PMID] 32517480.
2018
Clinical experience with ceftazidime/avibactam for treatment of antibiotic-resistant organisms other than Klebsiella pneumoniae.
International journal of antimicrobial agents. 51(4):629-635 [DOI] 10.1016/j.ijantimicag.2018.01.016. [PMID] 29408227.
2018
In Vitro Activity of Ceftolozane/Tazobactam vs Nonfermenting, Gram-Negative Cystic Fibrosis Isolates.
Open forum infectious diseases. 5(7) [DOI] 10.1093/ofid/ofy158. [PMID] 30046642.
2015
Ombitasvir/paritaprevir/ritonavir and dasabuvir tablets for hepatitis C virus genotype 1 infection.
The Annals of pharmacotherapy. 49(5):566-81 [DOI] 10.1177/1060028015570729. [PMID] 25680759.

Grants

May 2021 ACTIVE
Prevalence of Cefazolin Inoculum Effect in Mcthicillin Susceptible Staphylococcus aureus Bacteremia
Role: Co-Investigator
Funding: UF HEALTH SHANDS HOSPITAL

Education

Pharm.D.
2015 · Degreem Wingate University School of Pharmacy

Teaching Profile

Courses Taught
2019-2021
PHA5788C Patient Care 6
2020-2021
PHA5782C Patient Care 2: Introduction to Infectious Disease and Oncology
2020
PHA5755 Micro, Immun, Virol
2019
PHA5163L Prac Skills Lab III
2021
PHA5784C Pt Care 4: GI and Renal
2021
PHA5876C Pt Care 8 Complex Pts

Contact Details

Phones:
Business:
(352) 594-5892
Emails: